0
Posted by carry on 10 June, 2021 Views: 27 Points: 0
Now Buy Oxycodone 80 mg $$$$ 1***909***545***6717 Now Buy 2021/2036 $$$$, Oxycodone 80 mg Controlled-release products are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Initial dosing
Oxycodone 80 mg Opioid-naïve patients: 30 mg PO q12hr initially; titrate gradually every 1-2 days, increasing by 25-50% increments, with q12hr dosing interval maintained
A single dose >40 mg ER or total dose >80 mg ER are for use only in opioid-tolerant patients
Xtampza ER Opioid-naïve patients: 9 mg PO q12hr with food
Dosage Modifications
Coadministration with other CNS depressants: Initiate long-acting Oxycodone 80 mg with one-third to one-half the recommended starting dose; monitor for signs of respiratory depression, sedation, and hypotension
Conversion from other opioids to Oxycodone 80 mg Provide immediate-release opioids for breakthrough pain
Monitor patient closely for adverse effects or breakthrough pain during conversion and for several days following
Conversion from other oral Oxycodone 80 mg formulations
Conversion from other oral Oxycodone 80 mg formulations: Administer one-half of the patient's total daily PO Oxycodone 80 mg dose as q12hr
Conversion from fentanyl transdermal: Wait 18 hr after patch removed, then initiate conservative dose of ~10 mg q12hr Oxycodone 80 mg controlled-release for each 25 mcg/hr fentanyl transdermal patch
Conversion from fentanyl transdermal
Wait 18 hr after patch removed, then initiate conservative dose of ~10 mg q12hr Oxycodone 80 mg controlled-release for each 25 mcg/hr fentanyl transdermal patch
Conversion from other opioids to Xtampza ER
Conversion from other oral Oxycodone 80 mg formulations
Administer one-half of the patient's total daily PO Oxycodone 80 mg dose as q12hr with food
Because Xtampza ER is not bioequivalent to other Oxycodone 80 mg extended-release products
Monitor patients for possible dosage adjustment
Conversion from other opioids
Discontinue all other around-the clock opioid drugs
There are no established conversion ratios for conversion from other opioids to Xtampza ER defined by clinical trials
Initiate dosing using 9 mg PO q12hr with food and provide immediate-release rescue medication while stabilizing patient on Xtampza ER
Conversion from methadone
Close monitoring is of particular importance when converting from methadone to other opioid agonists; the ratio between methadone and other opioid agonists may vary widely as a function of previous dose exposure and methadone has a long half-life and can accumulate in the plasma
Conversion from fentanyl transdermal
18 hr following the removal of the transdermal fentanyl patch, initiate Xtampza ER; there has been no systematic essment of such conversion, a conservative Oxycodone 80 mg dose, ~9 mg (equivalent to 30 mg Oxycodone 80 mg HCl) q12hr should be initially substituted for each 25 mcg/hr fentanyl transdermal patch
Renal impairment
CrCl <60 mL/min: Serum concentration may increase by 50%; adjust dosage to response
Hepatic impairment
Reduce dosage in liver disease; decrease dosage of extended-release form to 1/3 or 1/2 of usual starting dosage; titrate to response
Alternative analgesics are recommended for patients who require a dose of Xtampza ER <9 mg
Dosing Considerations
Access to naloxone for opioid overdose
Assess need for naloxone upon initiating and renewing treatment
Consider prescribing naloxone
Based on patient’s risk factors for overdose (eg, concomitant use of CNS depressants, a history of opioid use disorder, prior opioid overdose); presence of risk factors should not prevent proper pain management
Household members (including children) or other close contacts at risk for accidental ingestion or overdose
Consult patients and caregivers on the following:
Availability of naloxone for emergency treatment of opioid overdose
Ways differ on how to obtain naloxone as permitted by individual state dispensing and prescribing requirements or guidelines (eg, by prescription, directly from a pharmacist, as part of a community-based program)
Discontinuation
Use a gradual downward titration of the dosage to avoid signs and symptoms of withdrawal in the physically-dependent patient
Do not abruptly discontinue Xtampza ER
Opioid-tolerant definition
Use of higher starting doses in patients who are not opioid-tolerant may cause fatal respiratory depression
Patients who are opioid-tolerant are those receiving, for 1 week or longer, at least 60 mg/day PO morphine, 25 mcg/hr transdermal fentanyl, 30 mg/day PO oxycodone, 8 mg/day PO hydromorphone, 25 mg/day PO oxymorphone, or an equianalgesic dose of another opioid
Limitations of use
Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve for patients whom alternative treatment options (eg, nonopioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain
Long-acting opioids are not indicated as a PRN analgesic



Affiliate Network Charity Commodities Entertainment Health & Wellness Home care Insuarance Materials for sale Medical MLM Business Opportunity MLM Business Plan MLM Marketing Plan MLM Software Mobile Online Marketing Other Online Marketing Pharmacy Real Estate Retail Social Networking Telecom & SMS Travel